Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3945156 | Gynecologic Oncology | 2012 | 8 Pages |
ObjectiveThese studies were designed to determine whether minocycline inhibits ovarian cancer growth in vitro and in vivo and the molecular mechanisms involved.Materials and methodsThe effect of minocycline on ovarian cancer cell proliferation, cell cycle progression and apoptosis was assessed using human ovarian cancer cell lines OVCAR-3, SKOV-3 and A2780. Then, the capacity of minocycline to inhibit growth of OVCAR-3 xenografts in female nude mice was examined.ResultsMinocycline inhibited cell proliferation and colony formation, down-regulated cyclins A, B and E leading to arrest of cells in the G0 phase of the cycle and suppression of DNA synthesis. Furthermore, exposure of these cells to minocycline led to DNA laddering, activation of caspase-3 and cleavage of PARP-1. In nude mice bearing sub-cutaneous tumors, minocycline suppressed tumor proliferation index, angiogenesis and tumor growth.ConclusionThese findings provide the initial basis for further evaluation of minocycline in the treatment of ovarian cancer.
► Minocycline interferes with the cell cycle progression of ovarian cancer cells. ► Minocycline inhibits cell proliferation and tumor growth. ► Treatment with minocycline confers survival advantage.